Percutaneous heart valves; past, present and future

MM Rozeik, DJ Wheatley, T Gourlay

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Percutaneous heart valves provide a promising future for patients refused surgery on the grounds of significant technical challenges or high risk for complications. Since the first human intervention more than 10 years ago, over 50 different types of valves have been developed. The CoreValve and Edwards SAPIEN valves have both experienced clinical trials and the latter has gained FDA approval for implantation in patients considered inoperable. Current complications, such as major vascular bleeding and stroke, prevent these valves from being commonly deployed in patients considered operable in conventional surgery. This review focuses on the past and present achievements of these valves and highlights the design considerations required to progress development further. It is envisaged that, with continued improvement in valve design and with increased clinical and engineering experience, percutaneous heart valve replacement may one day be a viable option for lower-risk operable patients.
LanguageEnglish
Pages397-410
Number of pages14
JournalPerfusion
Volume29
Issue number5
Early online date17 Mar 2014
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Heart Valves
Surgery
surgery
present
stroke
engineering
Biomedical Engineering
Blood Vessels
experience
Stroke
Clinical Trials
Hemorrhage

Keywords

  • transcatheter aortic valve replacement
  • percutaneous delivery
  • history
  • next generation valves

Cite this

Rozeik, MM ; Wheatley, DJ ; Gourlay, T. / Percutaneous heart valves; past, present and future. In: Perfusion. 2014 ; Vol. 29, No. 5. pp. 397-410.
@article{f5c9a5a37766412e8b534f45ef3e5da2,
title = "Percutaneous heart valves; past, present and future",
abstract = "Percutaneous heart valves provide a promising future for patients refused surgery on the grounds of significant technical challenges or high risk for complications. Since the first human intervention more than 10 years ago, over 50 different types of valves have been developed. The CoreValve and Edwards SAPIEN valves have both experienced clinical trials and the latter has gained FDA approval for implantation in patients considered inoperable. Current complications, such as major vascular bleeding and stroke, prevent these valves from being commonly deployed in patients considered operable in conventional surgery. This review focuses on the past and present achievements of these valves and highlights the design considerations required to progress development further. It is envisaged that, with continued improvement in valve design and with increased clinical and engineering experience, percutaneous heart valve replacement may one day be a viable option for lower-risk operable patients.",
keywords = "transcatheter aortic valve replacement, percutaneous delivery, history, next generation valves",
author = "MM Rozeik and DJ Wheatley and T Gourlay",
note = "(c) SAGE Publications.",
year = "2014",
month = "9",
doi = "10.1177/0267659114523464",
language = "English",
volume = "29",
pages = "397--410",
journal = "Perfusion",
issn = "0267-6591",
number = "5",

}

Percutaneous heart valves; past, present and future. / Rozeik, MM; Wheatley, DJ; Gourlay, T.

In: Perfusion, Vol. 29, No. 5, 09.2014, p. 397-410.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Percutaneous heart valves; past, present and future

AU - Rozeik, MM

AU - Wheatley, DJ

AU - Gourlay, T

N1 - (c) SAGE Publications.

PY - 2014/9

Y1 - 2014/9

N2 - Percutaneous heart valves provide a promising future for patients refused surgery on the grounds of significant technical challenges or high risk for complications. Since the first human intervention more than 10 years ago, over 50 different types of valves have been developed. The CoreValve and Edwards SAPIEN valves have both experienced clinical trials and the latter has gained FDA approval for implantation in patients considered inoperable. Current complications, such as major vascular bleeding and stroke, prevent these valves from being commonly deployed in patients considered operable in conventional surgery. This review focuses on the past and present achievements of these valves and highlights the design considerations required to progress development further. It is envisaged that, with continued improvement in valve design and with increased clinical and engineering experience, percutaneous heart valve replacement may one day be a viable option for lower-risk operable patients.

AB - Percutaneous heart valves provide a promising future for patients refused surgery on the grounds of significant technical challenges or high risk for complications. Since the first human intervention more than 10 years ago, over 50 different types of valves have been developed. The CoreValve and Edwards SAPIEN valves have both experienced clinical trials and the latter has gained FDA approval for implantation in patients considered inoperable. Current complications, such as major vascular bleeding and stroke, prevent these valves from being commonly deployed in patients considered operable in conventional surgery. This review focuses on the past and present achievements of these valves and highlights the design considerations required to progress development further. It is envisaged that, with continued improvement in valve design and with increased clinical and engineering experience, percutaneous heart valve replacement may one day be a viable option for lower-risk operable patients.

KW - transcatheter aortic valve replacement

KW - percutaneous delivery

KW - history

KW - next generation valves

UR - http://prf.sagepub.com/content/29/5/397.long

U2 - 10.1177/0267659114523464

DO - 10.1177/0267659114523464

M3 - Article

VL - 29

SP - 397

EP - 410

JO - Perfusion

T2 - Perfusion

JF - Perfusion

SN - 0267-6591

IS - 5

ER -